XBiotech Dividend Yield vs Price To Sales Ratio Analysis

XBIT Stock  USD 7.61  0.26  3.54%   
XBiotech financial indicator trend analysis is more than just analyzing XBiotech current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XBiotech is a good investment. Please check the relationship between XBiotech Dividend Yield and its Price To Sales Ratio accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XBiotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy XBiotech Stock please use our How to Invest in XBiotech guide.

Dividend Yield vs Price To Sales Ratio

Dividend Yield vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XBiotech Dividend Yield account and Price To Sales Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between XBiotech's Dividend Yield and Price To Sales Ratio is -0.33. Overlapping area represents the amount of variation of Dividend Yield that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of XBiotech, assuming nothing else is changed. The correlation between historical values of XBiotech's Dividend Yield and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Dividend Yield of XBiotech are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Dividend Yield i.e., XBiotech's Dividend Yield and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.33
Relationship DirectionNegative 
Relationship StrengthInsignificant

Dividend Yield

Dividend Yield is XBiotech dividend as a percentage of XBiotech stock price. XBiotech dividend yield is a measure of XBiotech stock productivity, which can be interpreted as interest rate earned on an XBiotech investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing XBiotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on XBiotech sales, a figure that is much harder to manipulate than other XBiotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.
Most indicators from XBiotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XBiotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XBiotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy XBiotech Stock please use our How to Invest in XBiotech guide.At this time, XBiotech's Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 1.49 in 2024, whereas Tax Provision is likely to drop slightly above 875 K in 2024.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation2.6M2.6M1.8M2.4M
Net Interest Income467K3.8M10.3M10.8M

XBiotech fundamental ratios Correlations

-0.090.870.881.00.47-0.990.90.240.990.910.990.620.680.590.250.90.441.00.630.540.990.330.550.960.24
-0.09-0.01-0.02-0.09-0.170.150.01-0.13-0.09-0.06-0.09-0.23-0.12-0.260.1-0.03-0.29-0.09-0.21-0.24-0.140.07-0.54-0.080.44
0.87-0.011.00.850.22-0.890.840.080.90.910.880.40.90.19-0.070.990.140.850.410.240.85-0.090.180.850.65
0.88-0.021.00.860.26-0.90.820.170.910.920.890.450.890.21-0.061.00.180.860.460.260.86-0.080.20.850.63
1.0-0.090.850.860.48-0.990.890.240.990.90.990.630.650.610.270.880.461.00.640.560.990.350.570.960.21
0.47-0.170.220.260.48-0.420.070.60.420.610.430.920.240.530.240.290.920.450.930.870.420.350.520.25-0.27
-0.990.15-0.89-0.9-0.99-0.42-0.9-0.22-1.0-0.91-0.99-0.59-0.71-0.57-0.16-0.92-0.41-0.99-0.6-0.5-0.99-0.28-0.55-0.96-0.27
0.90.010.840.820.890.07-0.9-0.070.910.720.90.220.590.460.250.840.080.910.220.210.920.30.410.980.34
0.24-0.130.080.170.240.6-0.22-0.070.210.310.220.63-0.010.170.130.180.520.230.640.240.180.150.20.08-0.13
0.99-0.090.90.910.990.42-1.00.910.210.911.00.590.70.570.170.920.410.990.590.490.990.280.530.960.3
0.91-0.060.910.920.90.61-0.910.720.310.910.910.710.840.380.060.930.50.890.730.580.880.080.370.80.41
0.99-0.090.880.890.990.43-0.990.90.221.00.910.60.680.590.160.910.420.990.60.510.990.30.550.960.26
0.62-0.230.40.450.630.92-0.590.220.630.590.710.60.380.550.140.470.870.60.990.860.570.230.550.4-0.15
0.68-0.120.90.890.650.24-0.710.59-0.010.70.840.680.38-0.05-0.140.870.080.650.410.260.65-0.330.020.620.68
0.59-0.260.190.210.610.53-0.570.460.170.570.380.590.55-0.050.180.260.720.610.530.690.610.780.950.55-0.54
0.250.1-0.07-0.060.270.24-0.160.250.130.170.060.160.14-0.140.18-0.050.140.270.150.260.250.450.130.28-0.3
0.9-0.030.991.00.880.29-0.920.840.180.920.930.910.470.870.26-0.050.210.880.480.290.88-0.040.240.870.6
0.44-0.290.140.180.460.92-0.410.080.520.410.50.420.870.080.720.140.210.430.850.880.420.460.70.25-0.43
1.0-0.090.850.861.00.45-0.990.910.230.990.890.990.60.650.610.270.880.430.610.530.990.350.570.970.21
0.63-0.210.410.460.640.93-0.60.220.640.590.730.60.990.410.530.150.480.850.610.850.570.240.530.41-0.12
0.54-0.240.240.260.560.87-0.50.210.240.490.580.510.860.260.690.260.290.880.530.850.520.380.670.36-0.36
0.99-0.140.850.860.990.42-0.990.920.180.990.880.990.570.650.610.250.880.420.990.570.520.330.580.980.2
0.330.07-0.09-0.080.350.35-0.280.30.150.280.080.30.23-0.330.780.45-0.040.460.350.240.380.330.680.34-0.57
0.55-0.540.180.20.570.52-0.550.410.20.530.370.550.550.020.950.130.240.70.570.530.670.580.680.51-0.6
0.96-0.080.850.850.960.25-0.960.980.080.960.80.960.40.620.550.280.870.250.970.410.360.980.340.510.26
0.240.440.650.630.21-0.27-0.270.34-0.130.30.410.26-0.150.68-0.54-0.30.6-0.430.21-0.12-0.360.2-0.57-0.60.26
Click cells to compare fundamentals

XBiotech Account Relationship Matchups

XBiotech fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets816.9M353.7M275.2M246.1M226.6M209.4M
Other Current Liab53.5M1.4M1.4M1.6M3.5M6.5M
Total Current Liabilities60.2M4.0M3.5M4.1M6.1M9.4M
Total Stockholder Equity755.6M348.6M269.4M240.4M218.8M199.2M
Property Plant And Equipment Net25.2M27.3M28.3M26.3M24.9M22.6M
Net Debt(714.6M)(237.4M)(237.0M)(157.3M)(200.0M)(210.0M)
Retained Earnings430.9M97.6M5.2M(27.7M)(52.3M)(54.9M)
Accounts Payable2.1M2.5M2.1M2.4M2.5M2.5M
Cash714.6M237.4M237.0M157.3M200.0M163.9M
Non Current Assets Total100.6M27.9M28.3M26.3M24.9M29.6M
Cash And Short Term Investments714.6M237.4M237.0M217.5M200.0M169.4M
Common Stock Total Equity324.8M249.8M262.3M267.3M307.4M244.1M
Common Stock Shares Outstanding46.3M30.8M30.0M30.4M30.4M36.4M
Liabilities And Stockholders Equity816.9M353.7M275.2M246.1M226.6M209.4M
Non Current Liabilities Total1.1M1.1M2.3M1.6M1.7M870.2K
Other Current Assets1.7M84.4M934K601K760K722K
Total Liab61.2M5.1M5.8M5.7M7.8M10.2M
Property Plant And Equipment Gross25.2M27.3M44.0M26.3M43.1M25.8M
Total Current Assets716.3M325.9M246.9M219.8M201.7M179.8M
Accumulated Other Comprehensive Income(255K)(106K)1.3M2.0M826K0.0
Common Stock324.8M249.8M262.3M267.3M271.2M248.6M
Property Plant Equipment25.2M27.3M28.3M26.3M30.2M20.6M
Net Tangible Assets755.6M348.6M269.4M240.4M276.5M236.7M
Other Stockholder Equity(255K)(106K)1.3M2.0M826K0.0
Other Liab1.1M1.1M2.3M1.6M1.9M2.0M
Retained Earnings Total Equity430.9M97.6M5.2M(27.7M)(31.9M)(33.5M)
Non Currrent Assets Other27.3M75M(1.1M)(1.7M)(1.5M)(1.4M)
Net Invested Capital755.6M348.6M269.4M240.4M218.8M304.0M
Net Working Capital656.1M321.9M243.4M215.8M195.6M263.6M
Capital Stock324.8M249.8M262.3M267.3M271.2M220.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for XBiotech Stock Analysis

When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.